GlassScriptPhysician profile
Naomi Jones
NPI 1790827194
$12,321.03
in general payments reported to CMS, 2019-2025
35 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,294 · 2022: $1,709 · 2023: $2,313 · 2024: $2,781 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,317 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,317.24 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,234.44 | 2021-2025 | Equetro, Equetro, Raldesy |
| Otsuka America Pharmaceutical, INC. | $1,215.14 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,160.24 | 2021-2025 | |
| Corium, LLC | $1,067.05 | 2021-2025 | Azstarys |
| Bausch Health US, LLC | $919.69 | 2021-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $915.09 | 2021-2024 | Trintellix |
| Almatica Pharma LLC | $746.76 | 2022-2025 | Loreev Xr, Gralise |
| Neos Therapeutics, LP | $734.51 | 2021-2025 | Adzenys Xr-Odt |
| Alkermes, INC. | $539.06 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Idorsia Pharmaceuticals US INC | $504.96 | 2022-2024 | Quviviq |
| Lundbeck LLC | $483.68 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $452.69 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $437.89 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $292.53 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $269.57 | 2024-2025 | Ingrezza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $183.03 | 2024-2025 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $164.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $158.17 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Eisai INC. | $137.06 | 2021-2022 | |
| Tris Pharma INC | $119.82 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $118.66 | 2021 | |
| Lilly USA, LLC | $62.81 | 2021-2023 | Jardiance, Emgality |
| Novo Nordisk INC | $54.00 | 2021 | |
| Axsome Therapeutics, INC. | $51.53 | 2023-2024 | Sunosi, Auvelity |
| Collegium Pharmaceutical, INC. | $48.92 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $48.65 | 2024 | Invega Trinza, Invega Sustenna |
| Amgen INC. | $45.85 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.07 | 2022-2023 | Belsomra |
| Aytu Biopharma, INC. | $23.53 | 2021 | |
| Ucb, INC. | $21.18 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.19 | 2025 | Relexxii |
| Noven Therapeutics, LLC | $16.86 | 2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $16.51 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $13.98 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.25 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.